Polymorph stabilities of pharmaceuticals used in the treatment of COVID-19

用于治疗 COVID-19 的药物的多晶型稳定性

• 批准号: 2589477
• 金额: --
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2589477
• 关键词: Polymorph; stabilities; pharmaceuticals; used; treatment

The aim of the project is to determine the pressure-sensitivity of COVID-19 related anti-viral active pharmaceutical ingredients (APIs). New polymorphs realised by high-pressure may i) have improved therapeutic properties or ii) identify potential limitations of the marketed form. New polymorphs and co-crystals will be characterized in-situ at high pressures using single-crystal and/or powder X-ray diffraction on beamline P02.2 at PETRA III and by other in-situ techniques such as Raman spectroscopy. Phase evolution of selected APIs will also be investigated on decompression which will help identify high-pressure phases that can be recovered at ambient conditions.

该项目的目的是确定COVID-19相关抗病毒活性药物成分（api）的压力敏感性。高压实现的新多态性可能i)改善治疗特性或ii)确定上市形式的潜在局限性。新的多晶和共晶将在PETRA III的P02.2光束线上使用单晶和/或粉末x射线衍射以及其他原位技术（如拉曼光谱）在高压下进行原位表征。所选api的相演化也将在减压时进行研究，这将有助于确定在环境条件下可以恢复的高压相。